GPCRs P2Y受体家族中偏倚信号传导的可能性。

IF 7.7 2区 医学 Q1 PHARMACOLOGY & PHARMACY
Claudia M Sisk, Simon Pitchford, Graham Ladds
{"title":"GPCRs P2Y受体家族中偏倚信号传导的可能性。","authors":"Claudia M Sisk, Simon Pitchford, Graham Ladds","doi":"10.1111/bph.70213","DOIUrl":null,"url":null,"abstract":"<p><p>The purinergic receptor family is primarily activated by nucleotides, and contains members of both the G protein coupled-receptor (GPCR) superfamily (P1 and P2Y) and ligand-gated ion channels (P2X). The P2Y receptors are widely expressed in the human body, and given the ubiquitous nature of nucleotides, purinergic signalling is involved with a plethora of molecular physiological functions. The widespread nature of P2Y receptors make them a viable therapeutic target, but with the negative risk of on-target side effects. Some of the side effects associated with P1 and P2Y receptors arise due to the pleiotropic nature of many GPCRs, because a singular GPCR can activate several G proteins, as well as recruit β-arrestins. The utilisation of ligands that exhibit downstream pathway-specific activation, also known as biased signalling, at the P2Y receptors could circumvent these issues. This review will cover the signalling nature and impact of the P2Y family, with an emphasis on individual activity patterns of the P2Y receptors. This review also discusses current literature on the development of biased ligands for these receptors, with an aim to highlight the most beneficial targets and outcomes.</p>","PeriodicalId":9262,"journal":{"name":"British Journal of Pharmacology","volume":" ","pages":""},"PeriodicalIF":7.7000,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The potential for biased signalling in the P2Y receptor family of GPCRs.\",\"authors\":\"Claudia M Sisk, Simon Pitchford, Graham Ladds\",\"doi\":\"10.1111/bph.70213\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The purinergic receptor family is primarily activated by nucleotides, and contains members of both the G protein coupled-receptor (GPCR) superfamily (P1 and P2Y) and ligand-gated ion channels (P2X). The P2Y receptors are widely expressed in the human body, and given the ubiquitous nature of nucleotides, purinergic signalling is involved with a plethora of molecular physiological functions. The widespread nature of P2Y receptors make them a viable therapeutic target, but with the negative risk of on-target side effects. Some of the side effects associated with P1 and P2Y receptors arise due to the pleiotropic nature of many GPCRs, because a singular GPCR can activate several G proteins, as well as recruit β-arrestins. The utilisation of ligands that exhibit downstream pathway-specific activation, also known as biased signalling, at the P2Y receptors could circumvent these issues. This review will cover the signalling nature and impact of the P2Y family, with an emphasis on individual activity patterns of the P2Y receptors. This review also discusses current literature on the development of biased ligands for these receptors, with an aim to highlight the most beneficial targets and outcomes.</p>\",\"PeriodicalId\":9262,\"journal\":{\"name\":\"British Journal of Pharmacology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":7.7000,\"publicationDate\":\"2025-10-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"British Journal of Pharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/bph.70213\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"British Journal of Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/bph.70213","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

嘌呤能受体家族主要由核苷酸激活,包含G蛋白偶联受体(GPCR)超家族(P1和P2Y)和配体门控离子通道(P2X)的成员。P2Y受体在人体中广泛表达,鉴于核苷酸的普遍性,嘌呤能信号传导参与了大量的分子生理功能。P2Y受体的广泛性使其成为可行的治疗靶点,但具有非靶点副作用的负面风险。与P1和P2Y受体相关的一些副作用是由于许多GPCR的多效性而产生的,因为单个GPCR可以激活几种G蛋白,并招募β-抑制蛋白。利用在P2Y受体上表现出下游通路特异性激活的配体,也称为偏置信号,可以避免这些问题。这篇综述将涵盖P2Y家族的信号性质和影响,重点是P2Y受体的个体活动模式。这篇综述还讨论了目前关于这些受体的偏置配体的发展的文献,旨在突出最有益的靶点和结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
The potential for biased signalling in the P2Y receptor family of GPCRs.

The purinergic receptor family is primarily activated by nucleotides, and contains members of both the G protein coupled-receptor (GPCR) superfamily (P1 and P2Y) and ligand-gated ion channels (P2X). The P2Y receptors are widely expressed in the human body, and given the ubiquitous nature of nucleotides, purinergic signalling is involved with a plethora of molecular physiological functions. The widespread nature of P2Y receptors make them a viable therapeutic target, but with the negative risk of on-target side effects. Some of the side effects associated with P1 and P2Y receptors arise due to the pleiotropic nature of many GPCRs, because a singular GPCR can activate several G proteins, as well as recruit β-arrestins. The utilisation of ligands that exhibit downstream pathway-specific activation, also known as biased signalling, at the P2Y receptors could circumvent these issues. This review will cover the signalling nature and impact of the P2Y family, with an emphasis on individual activity patterns of the P2Y receptors. This review also discusses current literature on the development of biased ligands for these receptors, with an aim to highlight the most beneficial targets and outcomes.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
15.40
自引率
12.30%
发文量
270
审稿时长
2.0 months
期刊介绍: The British Journal of Pharmacology (BJP) is a biomedical science journal offering comprehensive international coverage of experimental and translational pharmacology. It publishes original research, authoritative reviews, mini reviews, systematic reviews, meta-analyses, databases, letters to the Editor, and commentaries. Review articles, databases, systematic reviews, and meta-analyses are typically commissioned, but unsolicited contributions are also considered, either as standalone papers or part of themed issues. In addition to basic science research, BJP features translational pharmacology research, including proof-of-concept and early mechanistic studies in humans. While it generally does not publish first-in-man phase I studies or phase IIb, III, or IV studies, exceptions may be made under certain circumstances, particularly if results are combined with preclinical studies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信